NCT02400255View on ClinicalTrials.gov

Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Crenolanib besylate

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Arog Pharmaceuticals, Inc.

INDUSTRY